WHAT FACTORS INFLUENCE THE CHOICE OF APIXABAN, RIVAROXABAN, OR DABIGATRAN FOR STROKE PREVENTION AMONG ATRIAL FIBRILLATION …
Background Non-vitamin K oral anticoagulants (NOAC) are commonly prescribed to prevent
stroke for patients with atrial fibrillation (AF). We sought to assess factors which might …
stroke for patients with atrial fibrillation (AF). We sought to assess factors which might …
Cost-Effectiveness of Apixaban For Stroke Prevention In Atrial Fibrillation: An Kazakhstan Perspective
A Kostyuk, A Almadiyeva, T Nurgozhin - Value in Health, 2017 - valueinhealthjournal.com
Objectives Apixaban, dabigatran, and rivaroxaban are 3 novel oral anticoagulants (NOACs)
currently approved for stroke prevention in patients with atrial fibrillation (AF). Although …
currently approved for stroke prevention in patients with atrial fibrillation (AF). Although …
[HTML][HTML] Cost-effectiveness of apixaban compared to other anticoagulants in patients with atrial fibrillation in the real-world and trial settings
LA de Jong, J Groeneveld, J Stevanovic, H Rila… - PLoS …, 2019 - journals.plos.org
Introduction Randomized clinical trials (RCTs) and real-world data (RWD) in patients with
atrial fibrillation have shown that—compared to vitamin K antagonists (VKAs)—non-VKA oral …
atrial fibrillation have shown that—compared to vitamin K antagonists (VKAs)—non-VKA oral …
Safety and efficacy of apixaban in the treatment of atrial fibrillation
A Martin, R Stewart - Clinical Medicine Insights: Cardiology, 2012 - journals.sagepub.com
Atrial fibrillation is a common arrhythmia that increases the risk of stroke and systemic
embolism. Warfarin is a highly effective treatment in reducing this risk, but a narrow …
embolism. Warfarin is a highly effective treatment in reducing this risk, but a narrow …
Apixaban versus warfarin in Patients with Atrial Fibrillation in relation to Prior Warfarin Use: Insights from the ARISTOTLE trial
Background: Patients with atrial fibrillation (AF) who are new to anticoagulation (warfarin-
naïve [WN]) may have a higher risk of thrombosis and/or bleeding than patients who are …
naïve [WN]) may have a higher risk of thrombosis and/or bleeding than patients who are …
[HTML][HTML] ARISTOTLE reveals superiority of apixaban over warfarin in patients with atrial fibrillation
BM Mearns - Nature Reviews Cardiology, 2011 - nature.com
December 2006 and April 2010. Of the patients assigned to receive apixaban (n= 9,120) or
warfarin (n= 9,081), 15% had paroxysmal AF and 85% had persistent or permanent forms of …
warfarin (n= 9,081), 15% had paroxysmal AF and 85% had persistent or permanent forms of …
Cost-Effectiveness of Apixaban Versus Other New Oral Anticoagulants for the Prevention of Stroke: An Analysis of Patients with Atrial Fibrillation in Greece
K Athanasakis, D Arzoumanidou… - Value in …, 2013 - valueinhealthjournal.com
Objectives Apixaban, dabigatran (150 mg BID and 110 mg BID) and rivaroxaban are three
novel oral anticoagulants (NOACs) currently approved for stroke prevention and systemic …
novel oral anticoagulants (NOACs) currently approved for stroke prevention and systemic …
[引用][C] Aspirin plus apixaban Cost effectiveness of apixaban versus aspirin for stroke prevention in patients with non-valvular atrial fibrillation in Belgium
T Kongnakorn
Clinical outcomes in patients with atrial fibrillation according to sex during anticoagulation with apixaban or warfarin: a secondary analysis of a randomized controlled …
D Vinereanu, SR Stevens, JH Alexander… - European heart …, 2015 - academic.oup.com
Aim To assess clinical outcomes, efficacy, and safety according to sex during
anticoagulation with apixaban compared with warfarin in patients with atrial fibrillation …
anticoagulation with apixaban compared with warfarin in patients with atrial fibrillation …
[引用][C] Evidence summary on oral anticoagulants and stroke prevention in atrial fibrillation
NPS Medicinewise